Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials

Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. We evaluated the relationship between disease activity, according to Routine Assessment of Patient Index Data 3 (RAPID3) after 6-month treatment with tofacitinib, and long-term outcomes at 24 months. This was a...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Vibeke, Lee, Eun Bong, Yazici, Yusuf, Dikranian, Ara, Wilkinson, Bethanie, Takiya, Liza, Zang, Chuanbo, Bananis, Eustratios, Bergman, Martin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061070/
https://www.ncbi.nlm.nih.gov/pubmed/29656373
http://dx.doi.org/10.1007/s10067-018-4077-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061070/
https://www.ncbi.nlm.nih.gov/pubmed/29656373
http://dx.doi.org/10.1007/s10067-018-4077-3

Ejemplares similares